Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabozantinib - Exelixis/Ipsen

Drug Profile

Cabozantinib - Exelixis/Ipsen

Alternative Names: BMS-907351; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184

Latest Information Update: 10 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Exelixis; Ipsen; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Roche; Swedish Orphan Biovitrum; Takeda; University of Kansas Medical Center
  • Class Amides; Anilides; Antineoplastics; Cyclopropanes; Fluorine compounds; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors; Proto oncogene protein c ret inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Thyroid cancer
  • Registered Liver cancer
  • Phase II Adrenocortical carcinoma; Bone metastases; Brain metastases; Breast cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Head and neck cancer; Merkel cell carcinoma; Non-small cell lung cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Urogenital cancer; Uveal melanoma
  • Phase I/II Multiple myeloma; Solid tumours
  • Phase I Gastrointestinal cancer
  • No development reported Acute myeloid leukaemia; Astrocytoma; Cancer; Colorectal cancer; Glioblastoma
  • Discontinued Prostate cancer

Most Recent Events

  • 06 Dec 2018 Exelixis plans a phase III trial for Liver cancer (Combination therapy, First-line-therapy, Late-stage disease) (NCT03755791)
  • 15 Nov 2018 Registered for Liver cancer (Late-stage disease, Monotherapy, Second-line therapy or greater) in European Union, Norway, Iceland, Liechtenstein (PO)
  • 09 Nov 2018 Efficacy data from a phase III CELESTIAL trial in Liver cancer presented at the 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top